Saving Lives by
Innovative Genetic Engineering


  • Overview

    SL VaxiGen is R&D company dedicated to developing innovative vaccine therapeutics based on complementary platforms for saving lives.

    Our goal is to save lives by various innovative genetic and protein engineering technologies especially for infectious diseases and cancers.

  • Vision

    To become the leading global biotech company by developing innovative in-vivo gene therapeutics

  • Mission

    To save and improve the quality of patient’s lives with intractable diseases



  • June Young Park Ph.D.
    Executive VP, SL BIGEN
    VP, Buisness Division, ISU Abxis
    Post-doc fellowship, Harvard Medical School/Bringham and Women's Hospital
    Ph.D. Dept Life Science, POSTECH
    M.S./B.S. Dept life Science, POSTECH
  • Yong Bok Seo Ph.D.
    Senior manager, DNA Vaccine Team, SL BIGEN
    Post-doc fellowship, POSTECH-CATHOLIC Biomedical Engineering Inst.
    POSTECH, Ph.D.

Board of Director

  • Sang Sul Jung Ph.D.
    Catholic University of Korea, MD & Ph.D.
    Department of Surgery, College of Medicine, Catholic University of Korea, Professor, Head Professor
    Korea Breast Cancer Society, Chairman
    Korean Surgical Society, Chairman
  • Keun Tae Han Ph.D.
    University of Akron, Ph.D.
    University of Helsinki, MBA
    aSSIST, Professor
    LG Chem, Daewoo Motors, IBS Consulting
    Hans Consulting, CEO
  • Jun Chang. Ph.D.
    POSTECH, Ph.D.
    University of Virginia, Postdoc
    College of Pharmacy, Ewha Womans University, Professor
  • Kyung Hoon Cho.
    Department of Business Administration, Seoul National University, B.S.
    TS Investment, Vice president
  • Ji Won Kim.
    Department of Business Administration, Yonsei University B.S.
    Aju IB Investment, CEO
  • Chang Hoon Lee.
    Department of Biochemistry, Yonsei University, B.S.
    Sungkyunkwan University, MBA
    Kooksoondang Brewery, Advisor
    Leechanghoon Law Firm, Representative Attorney

Scientific Advisory Board

  • Yung Dae Yun. Ph.D.
    Michigan State University, Ph.D.
    MOGAM Institute for Biomedical Research, Vice President
    College of Natural Sciences, Ewha Womans University, Dean
  • Man Ki Song Ph.D.
    POSTECH, Ph.D.
    University of Maryland School of Medicine, Postdoc
    France INSERM, Researcher
    International Vaccine Institute, Senior Research Scientist
  • Eui-Cheol Shin, MD & Ph.D.
    Yonsei University, Ph.D.
    Graduate School of Medical Science and Engineering, KAIST, Professor
    Immunology working group member, ICE-HBV
    26th International Symposium on Hepatitis C Virus and Related Viruses, Organizer

DNA Vaccine Technology

  • Highly efficient vector
  • Antigen engineering

To induce antigen-specific strong and broad immunity, we combined the disease-specific multiple antigens and applied antigen engineering technologies such as codon optimization and gene shuffling in efficient expression vector system.

  • DNA Injection
  • Antigen expression
  • APC recruitment and activation
  • Induction of Ag-specific immune response

Plasmid DNA

B.S.A Platform Technology

  • Targeting vaccine-induced CTL immune response
  • Targeting vaccine-induced antibody immune response


The adaptive immunity which is mainly composed of T cell and B cell (antibody) plays an crucial role in prevention and/or treatment of diseases. Thus, increasing the specific immune response to a certain pathogen is important for the development immunotherapeutic. BSA, bi-specific adaptive adjuvant, is designed for increasing antigen-specific (or vaccine-induced) adaptive immune responses by binding two or more targets in simultaneously.
We have identified multiple potential mechanistic application of the BSA platform, including the three described below,

  • - Targeting to vaccine-induced CTLs. This version of BSA molecules enable the vaccine-induced CTL (cytotoxic T lymphocyte) to be selectively increased in the course of immune responses.
  • - Targeting to vaccine-induced GC B cells or TFH cells. This version of BSA molecules can stimulate the vaccine-induced GC B cells and/or TFH cell result in increase of vaccine-induced antibody responses.
  • - Simultaneous targeting of multiple co-stimulatory receptors or cytokine receptors, such as those involved in T cell responses and antibody responses. Combination of multiple co-stimulatory or cytokine receptors have resulted in significantly enhanced benefit than targeting any one of the targets of them separately. BSA is being developed for co-stimulation of effector T cell or B cells, could afford the clinical benefit of the combination together with the potential for synergistic, as well as significant advantages in manufacturing, simplified clinical development, and enhanced patient convenience.

Mode of Action (BSA for CTL response)

Mode of Action (BSA for antibody response)


이 표는 구성되어 있습니다.
Category Target Product Indication Development Stage
Research Preclinical Clinical
Infectious Diseases SL-V10 CMV/BKV+ Transplantation
SL-V20 Genital Herpes
Cancer SL-V60 GBM